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AbsTrACT
We report the case of a 61-year-od male, hospitalized for 
unstable angina. Coronary angiography showed a severe lesion 
in the middle third of the left anterior descending coronary 
artery. Percutaneous coronary intervention was performed 
with stent implantation. Coronary rupture was observed with 
contrast spilling to the left ventricle (type IV coronary perfo-
ration) immediately after balloon post-dilatation. After partial 
heparin reversal with protamine and prolonged balloon infla-
tion at low pressure, coronary rupture was controlled, with a 
good final angiographic result. Subsequent echocardiography 
showed minimal pericardial effusion. Post-procedure clinical 
follow-up was satisfactory.
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rEsUMO
Tratamento de Perfuração Coronária Tipo IV  
Durante Intervenção Coronária Percutânea
Relatamos o caso de um paciente de 61 anos de idade, 
hospitalizado por angina instável. Cineangiocoronariografia 
demonstrou lesão obstrutiva grave no terço médio da artéria 
descendente anterior. Intervenção coronária percutânea foi 
realizada com implante de stent. Logo depois da pós-dilatação 
com cateter-balão, observou-se ruptura coronária, com extra-
vasamento de contraste para o ventrículo esquerdo (perfuração 
coronária tipo IV). Após reversão parcial da heparina com 
protamina e insuflação prolongada do cateter-balão com baixa 
pressão, a ruptura coronária foi controlada, com bom resul-
tado angiográfico final. Ecocardiografia realizada em seguida 
evidenciou derrame pericárdico mínimo. A evolução clínica 
foi satisfatória após o procedimento.
DEsCrITOrEs: Angioplastia. Stents. Ruptura. Vasos coronários.
Case Report
C oronary perforation is a dreaded and potentially serious complication of percutaneous coronary interventions (PCIs), with high rates of morbidity 
and mortality.1 Perforation or frank rupture of coronary 
arteries are rare, occurring in 0.1% to 0.6% of patients 
undergoing PCI, reaching up to 3% of cases involving 
atheroablative techniques.1-5 The present study reports 
a case of coronary rupture (Ellis type IV perforation) 
draining into the left ventricle, successfully treated 
during the intervention.
Case report
Male patient, 61 years of age, smoker and hyper-
tensive, who underwent coronary artery bypass graft 
(CABG) in 2002 (free radial artery graft to the left 
anterior descending artery, as a “Y” saphenous vein 
graft to the first marginal branch of the left circumflex 
artery) after an acute myocardial infarction without 
ST-segment elevation. He was admitted at another 
hospital in early November 2011, with a diagnosis of 
unstable angina. On that occasion, he remained under 
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clinical treatment, with the use of acetylsalicylic acid, 
clopidogrel, enoxaparin, carvedilol, captopril, amlodi-
pine, and simvastatin. He was discharged after 72 hours 
with a scheduled coronary angiography within ten days.
The coronary angiography was performed at the 
Instituto Dante Pazzanese de Cardiologia using a 6F 
femoral sheath, which demonstrated the absence of 
significant atherosclerotic disease in the left main 
coronary artery, left circumflex artery, and right coro-
nary artery; severe stenosis in the middle third of the 
left anterior descending artery (Figure 1), with mild 
calcification, eccentricity and poststenotic dilatation; 
and ostial occlusion of the composite graft to the left 
anterior descending artery and first marginal branch 
of the left circumflex artery. Left ventriculography 
showed a slight reduction in left ventricular systolic 
function at the expense of mild overall deficit. Lesion 
assessment by quantitative coronary angiography 
(QCA) was performed off-line, using the CMS-GFTTM 
system, release 5.1 (Medis – Leiden, the Netherlands), 
which showed proximal reference diameter of 3.36 
mm, distal reference diameter of 4.11 mm, refer-
ence vessel diameter of 3.94 mm, minimum lumen 
diameter of 1.16 mm, stenosis area of 91.1%, and 
stenosis diameter of 70.6% (Figure 2).
After cardiac catheterization, it was decided, at 
a meeting involving clinical cardiologists and clinical 
interventionists, to perform a PCI to the left anterior 
descending artery.
procedure
The PCI was performed on November 22, 2011, 
through right radial approach, using a 6F sheath and 
Launcher EBU 3.5 guide-catheter (Medtronic Inc. – 
Minneapolis, USA). A 0.014-inch PT2 moderate support 
guidewire (Boston Scientific – Natick, USA) was intro-
duced and passed across the lesion in the left anterior 
descending artery, with direct implantation of a 4.0 × 24 
mm LibertéTM stent (Boston Scientific – Natick, United 
States) in the middle third of the anterior descending 
artery up to 12 atm (Figure 3A). Post-dilation was then 
performed with a 4.0 × 10 mm Hiryu® balloon catheter 
(Terumo – Tokyo, Japan) up to 18 atm (Figure 3B), after 
which the patient complained of acute and intense 
chest pain. QCA analysis was performed off-line after 
the procedure, showing a balloon-artery ratio of 1.07. 
A control angiography showed coronary rupture in the 
middle third of the left anterior descending artery, with 
extravasation as a continuous gush of contrast filling 
the left ventricular cavity (Ellis type IV coronary per-
foration) (Figure 3C and D). The balloon used for the 
post-dilation was quickly reinflated at the rupture site 
at low pressure (6 atm) (Figure 4A), which was main-
tained for 40 minutes. Partial reversal of unfractionated 
heparin with protamine sulfate was also performed. 
The right femoral artery was quickly accessed with a 
Figure 1 – Cranial view showing severe stenosis in the middle third 
of the left anterior descending artery.
Figure 3 – In A, direct implantation of a 4.0 × 24 mm LibertéTM stent 
in the middle third of the left anterior descending artery up to 12 atm. 
In B, post-dilation with 4.0 × 10 mm Hiryu® balloon catheter up to 
18 atm. In C and D, control angiography showing coronary rupture in 
the middle third of the left anterior descending artery, with continuous 
extravasation of contrast filling the left ventricular cavity (Ellis type IV 
coronary perforation).
Figure 2 – Quantitative coronary angiography of the left anterior des-
cending lesion. Proximal reference diameter (PRD) = 3.36 mm, distal 
reference diameter (DRD) = 4.11 mm, reference vessel diameter = 
3.94 mm, minimum lumen diameter (MLD) = 1.16 mm, stenosis area 
= 91.1%, and stenosis diameter = 70.6%.
PRD
MLD
DRD
7F sheath and the Judkins left 4.0 7F guide catheter 
was advanced to the left coronary sinus (double-guide 
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catheter technique). Subsequently, the 6F guide catheter 
was retrieved without deflating the balloon, and the 
left coronary artery was subselectively intubated with 
a 7F catheter; through that, a second 0.014-inch guide 
wire (BMW; Abbott Vascular – Temecula, United States) 
was advanced to the containment balloon, and, in a 
synchronized maneuver, the balloon was deflated, the 
second guide wire was crossed, and the containment 
balloon was reinflated (in order to minimize leakage 
of blood into the pericardium and the left ventricle). 
This second 0.014-inch guidewire would be used for 
delivering a coated stent (if necessary for the occlu-
sion of the coronary rupture), minimizing the time of 
deflation of the containment balloon. 
During prolonged balloon inflation, the patient 
remained hemodynamically stable, with no signs of 
cardiac tamponade, and there was improvement in 
chest pain. After balloon deflation, the patient had 
cardiorespiratory arrest in ventricular fibrillation, suc-
cessfully reversed after prompt defibrillation with 200 
J (biphasic) and cardiopulmonary resuscitation for 2 
minutes, with return to responsive sinus rhythm with 
hemodynamic stability, spontaneous ventilation, arterial 
oxygen saturation of 96%, blood pressure of 110/80 
mmHg, and asymptomatic. Control angiography revealed 
resolution of coronary rupture, the absence of any 
contrast extravasation, left anterior descending artery 
with no residual lesion in the middle third and TIMI 
3 flow (Fig.  4B). There was no need for coated stent 
implantation in the coronary rupture site. Transthoracic 
echocardiography performed in the catheterization lab 
showed minimal pericardial effusion.
After the procedure, the patient remained hospita-
lized in the Coronary Care Unit of the institution for 
52 hours, with satisfactory clinical evolution, despite 
the diagnosis of periprocedural myocardial infarction 
(creatine kinase MB fraction [CK-MB] mass, 51 ng/ mL; 
reference value, 4.1 ng/mL; troponin I, 0.57 ng/mL; 
reference value, 0.1 ng/mL). No other complications 
were observed, and transthoracic echocardiographies 
performed 24 and 48 hours after the procedure showed 
no pericardial effusion, and normal systolic and diastolic 
left ventricular function. The patient was discharged 
three days after the PCI, when a significant decrease 
in myocardial necrosis markers was observed.
The patient returned 30 days after the PCI procedure 
for outpatient consultation. He remained asymptomatic, 
using acetylsalicylic acid 100 mg, clopidogrel 75 mg, 
atenolol 50 mg, enalapril 20 mg every 12 hours, am-
lodipine 10 mg, and simvastatin 40 mg. Clopidogrel 
was then suspended, while the other medications were 
maintained. Clinical monitoring performed by telephone 
on May 4, 2012 showed no adverse cardiac events at 
the six-month follow-up.
DisCussion
Coronary perforation, albeit rare, is a severe and 
dramatic complication of PCI. In at least half of the 
cases it is caused by the intracoronary guide wire,6 and 
the use of atheroablation devices predisposes to this 
complication at higher frequency (1% vs. 0.2% when 
they are not used, P < 0.001).6 In the case of coronary 
perforation, impending cardiac tamponade requires 
rapid and accurate measures by the interventionist, at 
the risk of emergency surgery or death of the patient. 
Ellis et al.1 were the first to report, in 1994, the 
association between coronary perforations in PCIs and 
high incidence of major adverse events. In that study, 
the authors also proposed a classification of perfora-
tions, which is used to date: type I, extraluminal cavity 
without contrast extravasation (8% risk of tamponade); 
type II, presence of pericardial blush and myocardium 
without contrast extravasation (13% risk of tamponade); 
type III, contrast extravasation through outflow tract 
orifice > 1 mm (up to 63% risk of tamponade); and 
type IV, perforation draining into a heart chamber or 
coronary sinus (cavity spilling).
In addition to the atheroablative techniques, coronary 
perforation is associated with other risk factors related 
to the clinical features, the anatomy, and the technical 
approach, such as older age, female gender, chronic 
total occlusions, calcified lesions, significant tortuosity, 
use of high release or post-dilation pressures, balloon 
oversizing (balloon-artery ratio > 1.2), high pressure 
off the edges of the stent, and stenting in vessels with 
significant loss of distal calibre (tapering).3,5-7
Dippel et al.,3 in a series of 6,214 procedures 
performed between 1995 and 1999, observed that 
mortality was limited to the type III perforation sub-
group; no patient with type II perforation required 
emergency surgery or died. Mortality was 11.1%, need 
for emergency CABG was 22.2%, and the incidence of 
cardiac tamponade was 22.2%. In the series of coro-
nary perforation cases reported by Stankovic et al.,5 
the mortality rate was 8%, incidence of myocardial 
infarction was 18%, and CABG was necessary in 13% 
of cases. Witzke et al.6 reported, in their series, 39 
Figure 4 – In A, balloon reinsufflation used for post-dilation at the site 
of rupture at low pressure. In B, control angiography disclosing coronary 
rupture resolution and satisfactory angiographic result, with TIMI 3 flow.
A B
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perforations in 12,658 patients (0.3%). The mortality 
rate was 2.6%, the emergency surgery rate was 5.2%, 
and pericardial effusion occurred in 18 patients (46.2%), 
progressing to cardiac tamponade in seven (17.5%). The 
use of glycoprotein IIb/IIIa inhibitors did not change 
the outcome in this series, regarding adverse outcomes 
after coronary perforation. Silva et al.8 recently reported 
on the Brazilian experience when handling coronary 
perforations in a center with a high volume of proce-
dures. Of a total of 5,585 patients undergoing PCI, 18 
had coronary perforation (incidence of 0.32%), with 
no deaths. Emergency surgery was necessary in 5.6% 
of cases. Female gender, history of chronic obstruc-
tive pulmonary disease, and chronic occlusions were 
identified as predictors of coronary perforation. The 
observation of a chronological decrease in mortality in 
the series of reported cases can be explained both by 
the technological advancements of the specialty (the use 
of progressively smaller and more delicate devices and 
decrease in the use of atheroablative techniques) and 
the advent of coated stents and their positive impact 
on coronary perforation management.
Regarding the management and treatment, several 
authors have shown that the majority of the Ellis types 
I and II perforations can be conservatively treated, 
through reversal of unfractionated heparin with protamine 
(recommended dose: 1 mg intravenously for each 100 
units of unfractionated heparin administered), prolonged 
inflation with balloon catheter, and the use of coils and/
or stents when necessary. Types III and IV perforations 
may have major complications, often requiring more 
invasive measures, such as surgery and emergency 
pericardiocentesis.2,9-11 Transthoracic echocardiography 
is recommended while still in the catheterization lab, 
as well as other serial testing in the intensive care 
unit, due to the possibility of late formation of large 
pericardial effusion, which may cause hemodynamic 
compromise.8
Some emergency measures must be taken sequentially 
before the diagnosis of coronary perforation during PCI, 
such as heparin reversal, low-pressure prolonged infla-
tion (at least 10 minutes) of the balloon catheter at the 
perforation site, discontinuing or reversing glycoprotein 
IIb/IIIa inhibitors, performance of urgent echocardiog-
raphy, and performance of urgent pericardiocentesis if 
there are signs of cardiac tamponade. Heparin reversal 
is somewhat controversial, particularly with minor per-
forations, due to risk of acute stent thrombosis. Platelet 
transfusion is a good strategy to reverse glycoprotein 
IIb/IIIa inhibitors when using tirofiban or eptifibatide, 
which are highly specific for the IIb/IIIa receptor, with 
a half-life of two to three hours.12 However, it is worth 
remembering that abciximab has a long half-life (seven 
hours) and high affinity for the IIb/IIIa receptor, which 
can make it a less effective measure when this drug is 
used.13 If the perforation is not occluded, it is possible 
to use coated stent or microcoil implantation to occlude 
the perforation.14 CABG is indicated if these measures 
are not successful in controlling the perforation.
The use of coated stents for the treatment of coronary 
perforation has shown satisfactory results, with success 
rates > 90%. Currently, this is the treatment of choice 
for Ellis type III perforations in arteries > 2 mm.15 More 
modern possible techniques include device delivery 
through a 5F guide catheter (deeply intubated into the 
coronary artery) inside 6F or 7F guide catheters (mother-
and-child technique), as the high profile and reduced 
flexibility compromise the manoeuvres and the delivery 
capacity of the coated stent.16 The double-guide catheter 
technique may be used to minimize blood leakage into 
the pericardial when the coated stent implantation is 
necessary.17 This technique consists of a subselective 
catheterization of the coronary artery ostium through a 
second guide catheter, after obtaining a second access 
route, while keeping the containment balloon inflated 
at the perforation site. Through this catheter, the coated 
stent is delivered to seal the perforation. In the present 
case, the double-guide catheter technique was used, 
but the coated stent was not necessary, considering 
the complete resolution of coronary perforation at the 
control angiography after prolonged balloon inflation.
The reported case is relevant, as it documents 
a coronary perforation with extravasation of contrast 
medium into the left ventricle (Ellis type IV coronary 
perforation), a very rare complication. The probable 
cause of the rupture was the post-dilation at high 
pressure, reaching a high balloon-artery ratio. Although 
potentially severe, the event was well-managed and 
solved with the initial measures. The prolonged infla-
tion time of the containment balloon had a determinant 
role in the perforation control, and there was no need 
for coated stent implantation. However, this neces-
sity was foreseen, and, therefore, the double-guide 
catheter technique was employed, aiming at minimal 
interruption of balloon inflation at the perforation site. 
Cardiac arrest in ventricular fibrillation was attributed to 
reperfusion of the left anterior descending artery after 
cuff deflation. With immediate defibrillation, the rapid 
success of cardiopulmonary resuscitation prevented any 
neurological deficit, with very good long-term progno-
sis. The finding of periprocedural myocardial infarction 
was demonstrated by elevated markers of myocardial 
necrosis, which at first were attributed to prolonged 
myocardial ischaemia resulting from containment bal-
loon inflation. Nevertheless, this alteration should be 
considered a consequence of the complication that 
occurred, which evolved asymptomatically and without 
hemodynamic or electrical involvement.
It can be concluded that the successful treatment 
of this serious complication requires attention and rapid 
decision-making by the interventional cardiologist. Early 
detection of coronary perforation is crucial in order to 
perform prompt coronary artery occlusion with contain-
ment balloon. Heparin neutralization, albeit partial, can 
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be performed, as well as platelet transfusion in cases 
associated with the use of glycoprotein IIb/IIIa inhibitors 
and the use of coated stents. By becoming acquainted 
with these measures, the interventional cardiologist can 
prevent emergency surgery in most cases of coronary 
perforation and reduce morbidity and mortality from 
this complication.
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